New Hampshire Ends Medicaid Coverage for GLP-1 Obesity Drugs, Citing Jan. 1 Cost Cuts
Updated
Updated · Concord Monitor · Jun 2
New Hampshire Ends Medicaid Coverage for GLP-1 Obesity Drugs, Citing Jan. 1 Cost Cuts
3 articles · Updated · Concord Monitor · Jun 2
Summary
Jan. 1 marked the end of New Hampshire Medicaid coverage for GLP-1 drugs prescribed solely for obesity treatment, cutting off access for beneficiaries who rely on medicines such as Zepbound.
The state framed the move as a cost-cutting step, but critics argue it could raise longer-term spending as untreated obesity drives more diabetes, heart disease, kidney disease and hospitalizations.
GLP-1 access already faces hurdles beyond Medicaid — including prior authorizations, shifting co-pays and changing private-insurance coverage — leaving lower-income patients with no path to treatment after the state cutoff.
The dispute reflects a broader push to treat obesity as a chronic metabolic disease rather than a matter of willpower, with advocates urging New Hampshire to restore coverage regardless of income.
With federal aid now on the table, will New Hampshire restore access to life-changing obesity treatments?
These drugs prevent costly chronic illness, so why are states unable to afford covering them?
New Hampshire Ends Medicaid Coverage for GLP-1 Weight Loss Drugs: Financial Pressures, Health Equity, and National Trends
Overview
Starting January 1, 2026, New Hampshire’s Medicaid program will stop covering GLP-1 medications when prescribed only for weight loss, though coverage remains for other approved health conditions. This change means patients seeking GLP-1s for weight management must pay out-of-pocket or look for discount programs. The policy reflects growing financial pressures on state budgets due to the high cost and rising demand for these drugs. As a result, patients and providers must adapt to new payment options, while the state joins a national trend of limiting Medicaid coverage for expensive weight loss medications.